QHL-1848

QHL-1848 is a tumor microenvironment-activated albumin drug conjugate (ALDC) developed by Affinity Biopharmaceutical. It consists of the microtubule inhibitor eribulin conjugated to albumin via a proprietary TMEAlinker (TME-activated linker). This linker is specifically designed to be cleaved by extracellular legumain, an enzyme overexpressed in the tumor microenvironment that facilitates tumor invasion and metastasis. By leveraging this site-specific activation mechanism, QHL-1848 aims to deliver eribulin selectively to tumor tissues, thereby enhancing efficacy and reducing systemic toxicity. Preclinical evaluations in murine HT1080 xenograft models demonstrated complete tumor regression, and safety studies in dogs showed a significantly higher maximum tolerated dose compared to free eribulin.